Biomm

Biomm Days Inventory Outstanding

The Days Inventory Outstanding (DIO) of Biomm (BIOM3.SA) as of Nov 11, 2026 is 189.33. In the previous year, Days Inventory Outstanding (DIO) was 160.55 — a change of 17.92% (higher).

Days Inventory Outstanding

189.33

YoY

17.92%

Last updated:

Days Inventory Outstanding (DIO) of Biomm is 2025 189.33 . Days Inventory Outstanding (DIO) of Biomm was 2024 160.55 . It decreases by 17.92% higher compared to the previous year.

The Biomm Days Inventory Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Inventory Outstanding
Date
Days Inventory Outstanding
Jan 1, 2018
4,676.48 BRL
Jan 1, 2019
1,020.77 BRL
Jan 1, 2020
150.88 BRL
Jan 1, 2021
227.43 BRL
Jan 1, 2022
173.79 BRL
Jan 1, 2023
180.88 BRL
Jan 1, 2024
160.55 BRL
Jan 1, 2025
189.33 BRL
The Biomm Days Inventory Outstanding history
YEARDays Inventory OutstandingYoY
189.33+17.92%
160.55-11.24%
180.88+4.08%
173.79-23.59%
227.43+50.73%
150.88-85.22%
1,020.77-78.17%
4,676.48-94.77%
89,408.66+741.56%
10,624.11+1,401.45%
707.59—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomm stock

Days Inventory Outstanding (DIO) of Biomm is 189.33 in 2025.

Days Inventory Outstanding (DIO) of Biomm changed from 160.55 to 189.33, representing a 17.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Days Inventory Outstanding (DIO) Biomm since 2006 – with annual values, charts, and detailed analysis.

DIO measures the average number of days inventory is held before being sold. Lower values indicate more efficient inventory management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Inventory Outstanding (DIO)'s Biomm with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Inventory Outstanding (DIO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Inventory Outstanding (DIO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Biomm

All Key Metrics — Biomm